^
    2years
    Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. (PubMed, Breast Cancer Res Treat)
    In ER-negative and HER2-negative MedBC, the risk of recurrence and death was significantly lower than that of IDC, about half. Postoperative chemotherapy reduced recurrence and mortality. ER-positive and HER2-negative MedBC may have a lower risk of recurrence compared to IDC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER negative • ER positive + HER-2 negative • ER negative + HER-2 negative
    over2years
    CADENCE: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Mothaffar Rimawi | Trial completion date: Sep 2021 --> Sep 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative
    |
    carboplatin • docetaxel
    over2years
    The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer. (PubMed, Clin J Oncol Nurs)
    Patients with ER-positive MBC had greater odds of receiving quality end-of-life care than those with ER-negative MBC. HER2 status was not associated with differences in the quality of end-of-life care.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER negative • ER negative + HER-2 negative